: Akero Therapeutics shares plunge on liver disease treatment’s mixed results

Company’s lead product candidate shows some benefit for patients with cirrhosis due to fatty liver disease

Previous post : The portfolio designed to protect against big downward swings just had another big downward swing
Next post Brett Arends’s ROI: Nobel Prize–winning economist Claudia Goldin’s forgotten discovery